Review for QSAR studies and drug design of selected heterocyclic nucleus of antitubercular drugs

Abstract

This review article explores the pressing issue of drug-resistant strains of Mycobacterium tuberculosis, which have emerged due to the widespread and uncontrolled use of antibiotics in clinical settings over several decades. In response to this challenge, various methods have been developed for synthesizing new antitubercular compounds. Among these, the fragment-based drug discovery (FBDD) approach has shown promise as an effective strategy. One class of compounds that has exhibited significant potential in combating tuberculosis is 1,2-diazoles. The article discusses the importance of these compounds and their potential as future antitubercular drugs. Additionally, it delves into the various strategies employed in drug development, emphasizing the relevance and efficacy of FBDD. Analytical methods play a crucial role in characterizing antitubercular antibiotics, and the article highlights liquid chromatography and voltammetry as preferred techniques for determining these compounds. The redox (oxidation/reduction) properties of antituberculars make them amenable to analysis using electrochemical methods, with voltammetry being particularly suitable. Furthermore, the article underscores the significance of utilizing voltammetry for quantifying different categories of antibiotics in both dosage forms and human body fluids. The affordability of this method makes it particularly advantageous for developing countries, providing a cost-effective approach to monitor and assess the presence of antitubercular drugs. Overall, the review article offers valuable insights into the current strategies for addressing drug resistance in tuberculosis and highlights the potential of 1,2-diazoles as future antitubercular agents.